63449 Combined Skin Clearance and Quality of Life Response in Patients With Moderate-to-Severe Atopic Dermatitis With and Without Prior Systemic Exposure in the JADE Clinical Program

Abstract

Atopic dermatitis (AD) is characterized by eczematous skin lesions and impaired quality of life (QoL). This post hoc analysis included adults with moderate-to-severe AD who received abrocitinib (200/100 mg) or placebo as monotherapy (JADE MONO-1 NCT03349060]; MONO-2 NCT03575871]; 12 weeks), and abrocitinib or dupilumab 300 mg with concomitant topical therapy (DARE NCT04345367, 26 weeks]; COMPARE NCT03720470; 16 weeks]). Patients were stratified by baseline disease severity per Investigator's Global Assessment (moderate; severe) and treatment history (systemic-exposed; systemic-naive). Combined response of >=4-point improvement in Dermatology Life Quality Index and >=50% improvement in Eczema Area and Severity Index (DLQI>=4+EASI-50) was assessed. Week 12 DLQI>=4+EASI-50 response rates were greater with abrocitinib monotherapy versus placebo in systemic-exposed patients (moderate AD: 200 mg, 71.9% 23/32]; 100 mg, 45.9% 17/37] vs placebo, 4.8% 1/21]; severe AD: 73.3% 22/30]; 48.6% 18/37] vs 16.7% 2/12]) and systemic-naive patients (moderate AD: 200 mg, 69.6% 94/135]; 100 mg, 58.5% 72/123]; placebo, 17.9% 10/56]; severe AD: 58.2% 32/55]; 59.2% 29/49]; 12.9% 4/31]). In JADE DARE, comparable proportions achieved Week 16 DLQI>=4+EASI-50 response with abrocitinib and dupilumab across most severity strata and prior treatment exposure subgroups (systemic-exposed: moderate AD, abrocitinib, 75.3% 73/97] and dupilumab 72.3% 68/74]; severe AD, 77.3% 58/75] and 77.8% 63/81]; systemic-naive: moderate AD, 73.9% 85/115] and 73.4% 91/124]); response rates were higher with abrocitinib versus dupilumab for systemic-naive patients with severe AD (81.7% 58/71] vs 71.4% 45/63]). Results were similar at Week 16 in JADE COMPARE. Abrocitinib improved skin clearance and QoL, regardless of baseline disease severity or treatment history.Copyright © 2025